ArticleClinical and translational medicine2021
Tuning gut microbiota through a probiotic blend in gemcitabine-treated pancreatic cancer xenografted mice.
Article in Clinical and translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Can Complex 3D Models Effectively Replace 2D and Animal Models to Investigate the Microbe-Tumor-Immune Axis in Pancreatic Cancer Studies?Nutrients · 2026Review
- Gut microbiota and pancreatic cancer: tumorigenesis, progression, and clinical applications.Cancer biology & medicine · 2026Review
- Microbiota in pancreatic ductal adenocarcinoma progression and therapy: The hidden players.Chinese medical journal · 2026Review
- Article
- Biliary stents can modify the microbiota and promote the progression of pancreatic cancer.Frontiers in oncology · 2026Review
- Untargeted metabolomics reveals distinct metabolic profiles and putative bioactive metabolites in cell-free supernatants of food-grade microorganisms.Frontiers in microbiology · 2026Article
- Targeting the gut-pancreatic axis: microbial modulation of immunotherapy in pancreatic cancer.Frontiers in immunology · 2026Review
- Dysbiosis-NK Cell Crosstalk in Pancreatic Cancer: Toward a Unified Biomarker Signature for Improved Clinical Outcomes.International journal of molecular sciences · 2025Review
- Contributions of the Microbiome-Derived Metabolome for Risk Assessment and Prognostication of Pancreatic Cancer.Clinical chemistry · 2024Review
- Investigating the Influence of Gut Microbiota-related Metabolites in Gastrointestinal Cancer.Current cancer drug targets · 2024Review
- Review
- Review
- Review
- Counteracting gemcitabine+nab-paclitaxel induced dysbiosis in KRAS wild type and KRASCell death discovery · 2023Article
- Role of the Microbiota in Lung Cancer: Insights on Prevention and Treatment.International journal of molecular sciences · 2022Review
- Gut Dysbiosis in Pancreatic Diseases: A Causative Factor and a Novel Therapeutic Target.Frontiers in nutrition · 2022Review
- Association of the Microbiota and Pancreatic Cancer: Opportunities and Limitations.Frontiers in immunology · 2022Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.